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Résumé en
anglais
Glioblastoma is the most frequent primary malignant brain tumor in adults. Despite
treatments including surgery, radiotherapy and chemotherapy by oral
Temozolomide (TMZ), the prognosis of patients with glioblastoma remains very
poor. This is partly due to the resistance of malignant cells to therapy particularly
TMZ. Overexpression of epidermal growth factor receptor (EGFR) and Galectin-1 by
tumor cells significantly contributes to TMZ resistance. The purpose of this study
was to evaluate in vivo, the effect of local administration by convection enhanced
delivery (CED) of the anti-EGFR and anti-Galectin-1 siRNAs administered separately
or in combination on (i) the survival of nude mice-bearing orthotopic U87MG
glioblastoma cells and on (ii) the EGFR and Galectin-1 expression in excised U87MG
tumor tissue. Both siRNAs were carried by chitosan lipid nanocapsules (LNCs).
Survival of mice treated 14 days after tumor implantation by the combination of
anti-EGFR and anti-Galectin-1 siRNAs and TMZ (40mg/kg) was significantly
increased compared to animals treated by single anti-EGFR or anti-Galectin-1
siRNAs carried by chitosan-LNCs. This was confirmed by a decreased EGFR and
Galectin-1 expression at the protein level in excised U87MG tumor tissue, 8 days
post-transfection, visualized by immunofluorescence. This study demonstrates the
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